Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Extracellular vesicles from mature dendritic cells (DC) differentiate monocytes into immature DC.

Schierer S, Ostalecki C, Zinser E, Lamprecht R, Plosnita B, Stich L, Dörrie J, Lutz MB, Schuler G, Baur AS.

Life Sci Alliance. 2018 Dec 3;1(6):e201800093. doi: 10.26508/lsa.201800093. eCollection 2018 Dec.

2.

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Simon B, Wiesinger M, März J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, Dörrie J, Uslu U.

Int J Mol Sci. 2018 Aug 11;19(8). pii: E2365. doi: 10.3390/ijms19082365.

3.

The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.

Simon B, Harrer DC, Schuler-Thurner B, Schaft N, Schuler G, Dörrie J, Uslu U.

Exp Dermatol. 2018 Jul;27(7):769-778. doi: 10.1111/exd.13678.

PMID:
29704887
4.

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.

Dörrie J, Babalija L, Hoyer S, Gerer KF, Schuler G, Heinzerling L, Schaft N.

Int J Mol Sci. 2018 Jan 18;19(1). pii: E289. doi: 10.3390/ijms19010289.

5.

Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.

Harrer DC, Dörrie J, Schaft N.

Hum Gene Ther. 2018 May;29(5):547-558. doi: 10.1089/hum.2017.236. Epub 2018 Feb 27.

PMID:
29320890
6.

Proteomic Response of Human Umbilical Vein Endothelial Cells to Histamine Stimulation.

Emirbayer PE, Sinha A, Ignatchenko V, Hoyer S, Dörrie J, Schaft N, Pischetsrieder M, Kislinger T.

Proteomics. 2017 Nov;17(21). doi: 10.1002/pmic.201700116. Epub 2017 Oct 12.

PMID:
28921918
7.

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Harrer DC, Simon B, Fujii SI, Shimizu K, Uslu U, Schuler G, Gerer KF, Hoyer S, Dörrie J, Schaft N.

BMC Cancer. 2017 Aug 17;17(1):551. doi: 10.1186/s12885-017-3539-3.

8.

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.

Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S, Dörrie J.

Ther Adv Med Oncol. 2017 Jul;9(7):451-464. doi: 10.1177/1758834017712630. Epub 2017 Jun 13.

9.

Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.

Uslu U, Erdmann M, Schliep S, Dörrie J, Schaft N, Schuler G, Schuler-Thurner B.

Anticancer Res. 2017 Jun;37(6):3243-3248.

PMID:
28551671
10.
11.

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy.

Dörrie J.

EMBO Mol Med. 2017 Feb;9(2):135-136. doi: 10.15252/emmm.201607219. No abstract available.

12.

Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.

Uslu U, Schuler G, Dörrie J, Schaft N.

Exp Dermatol. 2016 Nov;25(11):872-879. doi: 10.1111/exd.13095. Epub 2016 Aug 3.

PMID:
27246630
13.

Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation.

Knippertz I, Deinzer A, Dörrie J, Schaft N, Nettelbeck DM, Steinkasserer A.

J Immunol Res. 2016;2016:6078473. doi: 10.1155/2016/6078473. Epub 2016 Jun 29.

14.

T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients.

Mummert C, Hofmann C, Hückelhoven AG, Bergmann S, Mueller-Schmucker SM, Harrer EG, Dörrie J, Schaft N, Harrer T.

AIDS. 2016 Sep 10;30(14):2149-58. doi: 10.1097/QAD.0000000000001176.

PMID:
27258398
15.

Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells.

Hoyer S, Gerer KF, Pfeiffer IA, Prommersberger S, Höfflin S, Jaitly T, Beltrame L, Cavalieri D, Schuler G, Vera J, Schaft N, Dörrie J.

J Immunol Res. 2015;2015:952184. doi: 10.1155/2015/952184. Epub 2015 Dec 28.

16.

Blockade of CCR7 leads to decreased dendritic cell migration to draining lymph nodes and promotes graft survival in low-risk corneal transplantation.

Hos D, Dörrie J, Schaft N, Bock F, Notara M, Kruse FE, Krautwald S, Cursiefen C, Bachmann BO.

Exp Eye Res. 2016 May;146:1-6. doi: 10.1016/j.exer.2015.12.004. Epub 2015 Dec 12.

PMID:
26689751
17.

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.

Krug C, Birkholz K, Paulus A, Schwenkert M, Schmidt P, Hoffmann N, Hombach A, Fey G, Abken H, Schuler G, Schuler-Thurner B, Dörrie J, Schaft N.

Cancer Immunol Immunother. 2015 Dec;64(12):1623-35. doi: 10.1007/s00262-015-1767-4. Epub 2015 Oct 29.

PMID:
26515978
18.

Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.

Höfflin S, Prommersberger S, Uslu U, Schuler G, Schmidt CW, Lennerz V, Dörrie J, Schaft N.

Cancer Biol Ther. 2015;16(9):1323-31. doi: 10.1080/15384047.2015.1070981. Epub 2015 Jul 15.

19.

Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells.

Shimizu K, Shinga J, Yamasaki S, Kawamura M, Dörrie J, Schaft N, Sato Y, Iyoda T, Fujii S.

PLoS One. 2015 Jun 29;10(6):e0131477. doi: 10.1371/journal.pone.0131477. eCollection 2015.

20.

Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.

Freimüller C, Stemberger J, Artwohl M, Germeroth L, Witt V, Fischer G, Tischer S, Eiz-Vesper B, Knippertz I, Dörrie J, Schaft N, Lion T, Fritsch G, Geyeregger R.

Cytotherapy. 2015 Jul;17(7):989-1007. doi: 10.1016/j.jcyt.2015.03.613. Epub 2015 Apr 9.

PMID:
25866178
21.

A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype.

Prommersberger S, Höfflin S, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.

Gene Ther. 2015 Jun;22(6):516-20. doi: 10.1038/gt.2015.15. Epub 2015 Mar 19.

PMID:
25786872
22.

Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.

Dörrie J, Krug C, Hofmann C, Müller I, Wellner V, Knippertz I, Schierer S, Thomas S, Zipperer E, Printz D, Fritsch G, Schuler G, Schaft N, Geyeregger R.

PLoS One. 2014 Oct 7;9(10):e109944. doi: 10.1371/journal.pone.0109944. eCollection 2014.

23.

Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango.

Hoyer S, Prommersberger S, Pfeiffer IA, Schuler-Thurner B, Schuler G, Dörrie J, Schaft N.

Eur J Immunol. 2014 Dec;44(12):3543-59. doi: 10.1002/eji.201444477. Epub 2014 Oct 27.

24.

Triggering of NF-κB in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy.

Pfeiffer IA, Hoyer S, Gerer KF, Voll RE, Knippertz I, Gückel E, Schuler G, Schaft N, Dörrie J.

Eur J Immunol. 2014 Nov;44(11):3413-28. doi: 10.1002/eji.201344417. Epub 2014 Sep 16.

25.

A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.

Krug C, Wiesinger M, Abken H, Schuler-Thurner B, Schuler G, Dörrie J, Schaft N.

Cancer Immunol Immunother. 2014 Oct;63(10):999-1008. doi: 10.1007/s00262-014-1572-5. Epub 2014 Jun 18.

PMID:
24938475
26.

Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells.

Kulzer L, Rubner Y, Deloch L, Allgäuer A, Frey B, Fietkau R, Dörrie J, Schaft N, Gaipl US.

J Immunotoxicol. 2014 Oct;11(4):328-36. doi: 10.3109/1547691X.2014.880533. Epub 2014 Feb 10.

PMID:
24512329
27.

CD8(+) T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?

Schaft N, Wellner V, Wohn C, Schuler G, Dörrie J.

Cancer Immunol Immunother. 2013 Dec;62(12):1769-80. doi: 10.1007/s00262-013-1481-z. Epub 2013 Oct 10.

PMID:
24114143
28.

Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes.

Pfeiffer IA, Zinser E, Strasser E, Stein MF, Dörrie J, Schaft N, Steinkasserer A, Knippertz I.

Immunobiology. 2013 Nov;218(11):1392-401. doi: 10.1016/j.imbio.2013.07.005. Epub 2013 Jul 25.

PMID:
23932569
29.

Just one position-independent lysine residue can direct MelanA into proteasomal degradation following N-terminal fusion of ubiquitin.

Setz C, Friedrich M, Hahn S, Dörrie J, Schaft N, Schuler G, Schubert U.

PLoS One. 2013;8(2):e55567. doi: 10.1371/journal.pone.0055567. Epub 2013 Feb 5.

30.

Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.

Riet T, Holzinger A, Dörrie J, Schaft N, Schuler G, Abken H.

Methods Mol Biol. 2013;969:187-201. doi: 10.1007/978-1-62703-260-5_12. Review.

PMID:
23296935
31.

Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.

Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada K, Dorrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii S.

Cancer Res. 2013 Jan 1;73(1):62-73. doi: 10.1158/0008-5472.CAN-12-0759. Epub 2012 Oct 29.

32.

Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.

Thomas S, Klobuch S, Besold K, Plachter B, Dörrie J, Schaft N, Theobald M, Herr W.

Eur J Immunol. 2012 Dec;42(12):3442-53. doi: 10.1002/eji.201242666. Epub 2012 Oct 1.

33.

HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients.

Etschel JK, Hückelhoven AG, Hofmann C, Zitzelsberger K, Maurer K, Bergmann S, Mueller-Schmucker SM, Wittmann J, Spriewald BM, Dörrie J, Schaft N, Harrer T.

J Immunol Methods. 2012 Jun 29;380(1-2):40-55. doi: 10.1016/j.jim.2012.03.005. Epub 2012 Apr 3.

PMID:
22510580
34.

Autocrine TNF is critical for the survival of human dendritic cells by regulating BAK, BCL-2, and FLIPL.

Lehner M, Kellert B, Proff J, Schmid MA, Diessenbacher P, Ensser A, Dörrie J, Schaft N, Leverkus M, Kämpgen E, Holter W.

J Immunol. 2012 May 15;188(10):4810-8. doi: 10.4049/jimmunol.1101610. Epub 2012 Apr 13.

35.

Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.

Lehner M, Götz G, Proff J, Schaft N, Dörrie J, Full F, Ensser A, Muller YA, Cerwenka A, Abken H, Parolini O, Ambros PF, Kovar H, Holter W.

PLoS One. 2012;7(2):e31210. doi: 10.1371/journal.pone.0031210. Epub 2012 Feb 15.

36.

Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes.

Hofmann C, Höfflin S, Hückelhoven A, Bergmann S, Harrer E, Schuler G, Dörrie J, Schaft N, Harrer T.

Blood. 2011 Nov 10;118(19):5174-7. doi: 10.1182/blood-2011-04-347005. Epub 2011 Sep 16.

37.

Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies.

Knippertz I, Stein MF, Dörrie J, Schaft N, Müller I, Deinzer A, Steinkasserer A, Nettelbeck DM.

Int J Hyperthermia. 2011;27(6):591-603. doi: 10.3109/02656736.2011.589234.

PMID:
21846195
38.

Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.

Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.

Blood. 2010 Sep 30;116(13):2277-85. doi: 10.1182/blood-2010-02-268425. Epub 2010 Jun 21.

39.

A fast and robust method to clone and functionally validate T-cell receptors.

Birkholz K, Hofmann C, Hoyer S, Schulz B, Harrer T, Kämpgen E, Schuler G, Dörrie J, Schaft N.

J Immunol Methods. 2009 Jul 31;346(1-2):45-54. doi: 10.1016/j.jim.2009.05.001. Epub 2009 May 7.

PMID:
19427315
40.

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.

Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kämpgen E, Schuler G, Abken H, Schaft N, Dörrie J.

Gene Ther. 2009 May;16(5):596-604. doi: 10.1038/gt.2008.189. Epub 2009 Jan 22.

PMID:
19158846
41.

Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA.

Hofmann C, Harrer T, Kubesch V, Maurer K, Metzner KJ, Eismann K, Bergmann S, Schmitt-Haendle M, Schuler G, Dörrie J, Schaft N.

AIDS. 2008 Aug 20;22(13):1577-82. doi: 10.1097/QAD.0b013e3283063a17.

PMID:
18670216
42.

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.

Melanoma Res. 2008 Apr;18(2):73-84. doi: 10.1097/CMR.0b013e3282f7c8f9.

43.

Dendritic cell vaccination and other strategies to tip the balance of the immune system : DC2007 5th International Meeting, July 16-18, Bamberg, Germany.

Schaft N, Birkholz K, Hofmann C, Schmid M, Theiner G, Dörrie J.

Cancer Immunol Immunother. 2008 Jun;57(6):913-28. doi: 10.1007/s00262-007-0443-8. Epub 2008 Jan 31. No abstract available.

PMID:
18236041
44.

Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes.

Dörrie J, Schaft N, Müller I, Wellner V, Schunder T, Hänig J, Oostingh GJ, Schön MP, Robert C, Kämpgen E, Schuler G.

Cancer Immunol Immunother. 2008 Apr;57(4):467-77. Epub 2007 Sep 2.

PMID:
17768622
45.

Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.

Erdmann M, Dörrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G, Schuler-Thurner B.

J Immunother. 2007 Sep;30(6):663-74.

PMID:
17667530
46.

Strategies for immune intervention; from bench to bedside: Symposium 2006 of the Collaborative Research Center "Strategies of cellular immune intervention" July 17th-18th, Erlangen, Germany.

Dörrie J, Birkholz K, Schaft N.

Cancer Immunol Immunother. 2007 Oct;56(10):1677-85. Epub 2007 Mar 29. No abstract available.

PMID:
17393161
47.

An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: implications for tumor antigen detection and amplification.

Dörrie J, Wellner V, Kämpgen E, Schuler G, Schaft N.

J Immunol Methods. 2006 Jun 30;313(1-2):119-28. Epub 2006 May 16.

PMID:
16780866
48.

Strategies for immune intervention.

Schaft N, Dörrie J.

Cancer Immunol Immunother. 2006 May;55(5):612-22. Epub 2005 Dec 16. No abstract available.

PMID:
16362408
49.

A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes.

Schaft N, Dörrie J, Müller I, Beck V, Baumann S, Schunder T, Kämpgen E, Schuler G.

Cancer Immunol Immunother. 2006 Sep;55(9):1132-41. Epub 2005 Dec 13.

PMID:
16344988
50.

Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.

Schaft N, Dörrie J, Thumann P, Beck VE, Müller I, Schultz ES, Kämpgen E, Dieckmann D, Schuler G.

J Immunol. 2005 Mar 1;174(5):3087-97. Erratum in: J Immunol. 2005 May 1;174(9):5884.

Supplemental Content

Loading ...
Support Center